BioCentury
ARTICLE | Company News

Betta, Tyrogenex form JV for RCC candidate

September 1, 2017 3:17 PM UTC

Betta Pharmaceuticals Co. Ltd. (SZSE:300558) and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's vorolanib (X-82, CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex following a $10 million investment.

In June, Betta gained Chinese rights to vorolanib when it acquired Anew Pharmaceutical Science and Technology (Shanghai) Co. Ltd...